{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:29Z","timestamp":1772136329460,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007149","name":"Genopole","doi-asserted-by":"publisher","award":["ATIGE 2020"],"award-info":[{"award-number":["ATIGE 2020"]}],"id":[{"id":"10.13039\/501100007149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007149","name":"Genopole","doi-asserted-by":"publisher","award":["ATIGE 2020"],"award-info":[{"award-number":["ATIGE 2020"]}],"id":[{"id":"10.13039\/501100007149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22470-9","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:01:54Z","timestamp":1762282914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined effects of restriction factors and transduction adjuvants on lentiviral vector gene transfer efficacy"],"prefix":"10.1038","volume":"15","author":[{"given":"Marie","family":"Dewannieux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Fofana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Mormin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Galy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"6","key":"22470_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41577-021-00626-8","volume":"22","author":"S Majdoul","year":"2022","unstructured":"Majdoul, S. & Compton, A. A. Lessons in self-defence: Inhibition of virus entry by intrinsic immunity. Nat. Rev. Immunol. 22(6), 339\u2013352 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"22470_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature15399","volume":"526","author":"A Rosa","year":"2015","unstructured":"Rosa, A. et al. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526, 212\u2013217 (2015).","journal-title":"Nature"},{"key":"22470_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nature15400","volume":"526","author":"Y Usami","year":"2015","unstructured":"Usami, Y., Wu, Y. & G\u00f6ttlinger, H. G. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526, 218\u2013223 (2015).","journal-title":"Nature"},{"issue":"1","key":"22470_CR4","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1038\/s41467-023-39262-2","volume":"14","author":"SA Leonhardt","year":"2023","unstructured":"Leonhardt, S. A. et al. Antiviral HIV-1 SERINC restriction factors disrupt virus membrane asymmetry. Nat. Commun. 14(1), 4368 (2023).","journal-title":"Nat. Commun."},{"issue":"7","key":"22470_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/v13071279","volume":"13","author":"WE Diehl","year":"2021","unstructured":"Diehl, W. E. et al. Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity. Viruses 13(7), 1279 (2021).","journal-title":"Viruses"},{"key":"22470_CR6","doi-asserted-by":"publisher","first-page":"1516806","DOI":"10.3389\/fcimb.2024.1516806","volume":"14","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. SERINC5 counters retroviruses and non-retroviruses. Front. Cell Infect. Microbiol. 14, 1516806 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"5","key":"22470_CR7","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1128\/JVI.01531-10","volume":"85","author":"J Lu","year":"2011","unstructured":"Lu, J. et al. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85(5), 2126\u20132137 (2011).","journal-title":"J. Virol."},{"issue":"1","key":"22470_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12977-017-0377-y","volume":"14","author":"G Shi","year":"2017","unstructured":"Shi, G., Schwartz, O. & Compton, A. A. More than meets the I: The diverse antiviral and cellular functions of interferon-induced transmembrane proteins. Retrovirology 14(1), 53 (2017).","journal-title":"Retrovirology"},{"issue":"5","key":"22470_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/v16050734","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. The antiviral activity of interferon-induced transmembrane proteins and virus evasion strategies. Viruses 16(5), 734 (2024).","journal-title":"Viruses"},{"key":"22470_CR10","doi-asserted-by":"crossref","unstructured":"Agarwal, M., et al., Restriction of HIV-1 infectivity by interferon and IFITM3 is counteracted by Nef. bioRxiv, 2025.","DOI":"10.1101\/2025.05.15.654345"},{"issue":"1","key":"22470_CR11","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.1038\/s41598-018-32785-5","volume":"8","author":"WJ Lee","year":"2018","unstructured":"Lee, W. J. et al. IFITM proteins inhibit HIV-1 protein synthesis. Sci. Rep. 8(1), 14551 (2018).","journal-title":"Sci. Rep."},{"issue":"1","key":"22470_CR12","doi-asserted-by":"publisher","first-page":"10\u20131128","DOI":"10.1128\/mBio.03088-19","volume":"11","author":"YS Ahi","year":"2020","unstructured":"Ahi, Y. S. et al. IFITM3 reduces retroviral envelope abundance and function and is counteracted by glycoGag. MBio 11(1), 10\u20131128 (2020).","journal-title":"MBio"},{"issue":"2","key":"22470_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s44318-024-00334-8","volume":"44","author":"K Rahman","year":"2025","unstructured":"Rahman, K. et al. SNARE mimicry by the CD225 domain of IFITM3 enables regulation of homotypic late endosome fusion. EMBO J. 44(2), 534\u2013562 (2025).","journal-title":"EMBO J."},{"issue":"8","key":"22470_CR14","doi-asserted-by":"publisher","first-page":"e104341","DOI":"10.1371\/journal.pone.0104341","volume":"9","author":"S Weston","year":"2014","unstructured":"Weston, S. et al. A membrane topology model for human interferon inducible transmembrane protein 1. PLoS ONE 9(8), e104341 (2014).","journal-title":"PLoS ONE"},{"issue":"9","key":"22470_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/tra.12416","volume":"17","author":"S Weston","year":"2016","unstructured":"Weston, S. et al. Alphavirus restriction by IFITM proteins. Traffic 17(9), 997\u20131013 (2016).","journal-title":"Traffic"},{"issue":"6","key":"22470_CR16","doi-asserted-by":"publisher","first-page":"10\u2013128","DOI":"10.1128\/JVI.02003-18","volume":"93","author":"SE Smith","year":"2019","unstructured":"Smith, S. E. et al. Interferon-induced transmembrane protein 1 restricts replication of viruses that enter cells via the plasma membrane. J. Virol. 93(6), 10\u2013128 (2019).","journal-title":"J. Virol."},{"key":"22470_CR17","doi-asserted-by":"crossref","unstructured":"Wilt, I., et al., IFITM1 and IFITM3 cooperate to restrict virus entry in endolysosomes. bioRxiv, 2025: p. 2025.06.01.657267.","DOI":"10.1101\/2025.06.01.657267"},{"issue":"6304","key":"22470_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.aah6192","volume":"353","author":"L Naldini","year":"2016","unstructured":"Naldini, L., Trono, D. & Verma, I. M. Lentiviral vectors, two decades later. Science 353(6304), 1101\u20131102 (2016).","journal-title":"Science"},{"issue":"9","key":"22470_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R. et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15(9), 871\u2013875 (1997).","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"22470_CR20","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72(11), 8463\u20138471 (1998).","journal-title":"J. Virol."},{"issue":"2","key":"22470_CR21","doi-asserted-by":"publisher","first-page":"mjae005","DOI":"10.1093\/jmcb\/mjae005","volume":"16","author":"D Kmiec","year":"2024","unstructured":"Kmiec, D. & Kirchhoff, F. Antiviral factors and their counteraction by HIV-1: many uncovered and more to be discovered. J. Mol. Cell Biol. 16(2), mjae005 (2024).","journal-title":"J. Mol. Cell Biol."},{"issue":"9","key":"22470_CR22","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2013-11-540641","volume":"123","author":"F Amirache","year":"2014","unstructured":"Amirache, F. et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 123(9), 1422\u20131424 (2014).","journal-title":"Blood"},{"issue":"13","key":"22470_CR23","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1182\/blood-2008-05-155945","volume":"112","author":"C Frecha","year":"2008","unstructured":"Frecha, C. et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112(13), 4843\u20134852 (2008).","journal-title":"Blood"},{"issue":"15","key":"22470_CR24","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1182\/blood-2009-05-220798","volume":"114","author":"C Frecha","year":"2009","unstructured":"Frecha, C. et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114(15), 3173\u20133180 (2009).","journal-title":"Blood"},{"issue":"8","key":"22470_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","volume":"124","author":"A Girard-Gagnepain","year":"2014","unstructured":"Girard-Gagnepain, A. et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 124(8), 1221\u20131231 (2014).","journal-title":"Blood"},{"issue":"12","key":"22470_CR26","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/jth.13520","volume":"14","author":"C Levy","year":"2016","unstructured":"Levy, C. et al. Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD\/SCIDgammac(-\/-) mice. J. Thromb. Haemost. 14(12), 2478\u20132492 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"22470_CR27","unstructured":"Stable pseudotyped lentiviral particles and uses thereof. Inventor Anne Galy. Assigned to Institut National de la Sante et de la Recherche Medicale INSERM, Genethon, Universite D\u2019Evry Val D\u2019Essonne, Filed 2017\u201304\u201321 and publication of US11993781B2 on 2024\u201305\u201328."},{"issue":"7\u20138","key":"22470_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41434-024-00454-0","volume":"31","author":"A Renner","year":"2024","unstructured":"Renner, A. et al. Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells. Gene Ther. 31(7\u20138), 378\u2013390 (2024).","journal-title":"Gene Ther."},{"issue":"9","key":"22470_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/v12091016","volume":"12","author":"A Gutierrez-Guerrero","year":"2020","unstructured":"Gutierrez-Guerrero, A., Cosset, F. L. & Verhoeyen, E. Lentiviral vector pseudotypes: Precious tools to improve gene modification of hematopoietic cells for research and gene therapy. Viruses 12(9), 1016 (2020).","journal-title":"Viruses"},{"issue":"3","key":"22470_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/0042-6822(69)90154-8","volume":"38","author":"K Toyoshima","year":"1969","unstructured":"Toyoshima, K. & Vogt, P. K. Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology 38(3), 414\u2013426 (1969).","journal-title":"Virology"},{"issue":"2","key":"22470_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0166-0934(89)90132-8","volume":"23","author":"K Cornetta","year":"1989","unstructured":"Cornetta, K. & Anderson, W. F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: Implications for human gene therapy. J. Virol. Methods 23(2), 187\u2013194 (1989).","journal-title":"J. Virol. Methods"},{"issue":"2","key":"22470_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jgm.1429","volume":"12","author":"M Wurm","year":"2010","unstructured":"Wurm, M. et al. The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. J. Gene Med. 12(2), 137\u2013146 (2010).","journal-title":"J. Gene Med."},{"issue":"8","key":"22470_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nm0896-876","volume":"2","author":"H Hanenberg","year":"1996","unstructured":"Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2(8), 876\u2013882 (1996).","journal-title":"Nat. Med."},{"key":"22470_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.omtm.2018.08.002","volume":"10","author":"M Delville","year":"2018","unstructured":"Delville, M. et al. A nontoxic transduction enhancer enables highly efficient lentiviral transduction of primary murine T cells and hematopoietic stem cells. Mol. Ther. Methods Clin. Dev. 10, 341\u2013347 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"22470_CR35","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1038\/mtna.2013.17","volume":"2","author":"D Fenard","year":"2013","unstructured":"Fenard, D. et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol. Ther. Nucleic Acids 2(5), e90 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"22470_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.omtm.2017.02.003","volume":"5","author":"C Piovan","year":"2017","unstructured":"Piovan, C. et al. Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes. Mol Ther Methods Clin Dev 5, 22\u201330 (2017).","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"22470_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/blood-2013-12-546218","volume":"124","author":"CX Wang","year":"2014","unstructured":"Wang, C. X. et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 124(6), 913\u2013923 (2014).","journal-title":"Blood"},{"issue":"43","key":"22470_CR38","doi-asserted-by":"publisher","first-page":"E10069","DOI":"10.1073\/pnas.1811892115","volume":"115","author":"G Shi","year":"2018","unstructured":"Shi, G. et al. mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3. Proc Natl Acad Sci U S A 115(43), E10069\u2013E10078 (2018).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"22470_CR39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood.2019000040","volume":"134","author":"S Ozog","year":"2019","unstructured":"Ozog, S. et al. Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes. Blood 134(16), 1298\u20131311 (2019).","journal-title":"Blood"},{"issue":"6","key":"22470_CR40","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.stem.2018.10.008","volume":"23","author":"C Petrillo","year":"2018","unstructured":"Petrillo, C. et al. Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells. Cell Stem Cell 23(6), 820\u2013832 (2018).","journal-title":"Cell Stem Cell"},{"key":"22470_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.omtm.2019.11.021","volume":"17","author":"CB Ferreira","year":"2020","unstructured":"Ferreira, C. B. et al. Lentiviral vector production titer is not limited in HEK293T by induced intracellular innate immunity. Mol. Ther. Methods Clin. Dev. 17, 209\u2013219 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"22470_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/mt.2009.282","volume":"18","author":"GD Trobridge","year":"2010","unstructured":"Trobridge, G. D. et al. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol. Ther. 18(4), 725\u2013733 (2010).","journal-title":"Mol. Ther."},{"issue":"7","key":"22470_CR43","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1128\/JVI.75.7.3488-3489.2001","volume":"75","author":"DS An","year":"2001","unstructured":"An, D. S., Xie, Y. M. & Chen, I. S. Y. Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus envelope. J. Virol. 75(7), 3488\u20133489 (2001).","journal-title":"J. Virol."},{"key":"22470_CR44","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1128\/JVI.76.13.6442-6452.2002","volume":"76","author":"D Lavillette","year":"2002","unstructured":"Lavillette, D. et al. The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters\/cell surface receptors. J. Virol. 76, 6442\u20136452 (2002).","journal-title":"J. Virol."},{"issue":"3","key":"22470_CR45","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/bloodadvances.2018027508","volume":"3","author":"O Bernadin","year":"2019","unstructured":"Bernadin, O. et al. Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency. Blood Adv. 3(3), 461\u2013475 (2019).","journal-title":"Blood Adv."},{"issue":"21\u201322","key":"22470_CR46","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1089\/hum.2024.098","volume":"35","author":"M Mormin","year":"2024","unstructured":"Mormin, M. et al. Cyclosporin H improves the transduction of CD34(+) cells with an anti-sickling globin vector, a possible therapeutic approach for sickle cell disease. Hum. Gene Ther. 35(21\u201322), 896\u2013903 (2024).","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"22470_CR47","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.15252\/embr.201642771","volume":"17","author":"AA Compton","year":"2016","unstructured":"Compton, A. A. et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. EMBO Rep. 17(11), 1657\u20131671 (2016).","journal-title":"EMBO Rep."},{"key":"22470_CR48","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1128\/JVI.74.7.3321-3329.2000","volume":"74","author":"JL Blond","year":"2000","unstructured":"Blond, J. L. et al. An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J. Virol. 74, 3321\u20133329 (2000).","journal-title":"J. Virol."},{"issue":"6","key":"22470_CR49","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1073\/pnas.0305763101","volume":"101","author":"F Mallet","year":"2004","unstructured":"Mallet, F. et al. The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology. Proc. Natl. Acad. Sci. U S A 101(6), 1731\u20131736 (2004).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1","key":"22470_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/hgtb.2013.090","volume":"25","author":"D Ingrao","year":"2014","unstructured":"Ingrao, D. et al. Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Hum. Gene Ther. Methods 25(1), 48\u201356 (2014).","journal-title":"Hum. Gene Ther. Methods"},{"key":"22470_CR51","doi-asserted-by":"crossref","unstructured":"Shi, G., et al., Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J Clin Invest, 132(24) 2022.","DOI":"10.1172\/JCI160766"},{"key":"22470_CR52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.omtm.2018.10.014","volume":"11","author":"V Poletti","year":"2018","unstructured":"Poletti, V. et al. Pre-clinical development of a lentiviral vector expressing the anti-sickling betaAS3 globin for gene therapy for sickle cell disease. Mol. Ther. Methods Clin. Dev. 11, 167\u2013179 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"9","key":"22470_CR53","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41434-022-00315-8","volume":"29","author":"G Corre","year":"2022","unstructured":"Corre, G. et al. Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells. Gene Ther. 29(9), 536\u2013543 (2022).","journal-title":"Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22470-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:03:35Z","timestamp":1762286615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22470-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22470"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22470-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6702056\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author A. Galy is inventor of a patent entitled \u201c Stable pseudotyped lentiviral particles and uses thereof \u201c published as US11993781B2. The other authors have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38643"}}